However, this is one of the few studies that took into consideration both the prevalence of non-AD comorbidities and the FDG PET hypometabolism pattern in the context of interpreting isolated Aβ positivity and establishing the clinical applicability of tau biomarkers. Here, MAPT is linked to Alzheimer disease.